Losartan Potassium Tablet, Film Coated
Product Images NDC 51655-791

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 51655-791). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (51655 791 52 Master Bottle Label Approval Rev A 01 22)

Label (51655 791 52 Master Bottle Label Approval Rev A 01 22)
Losartan Potassium is a prescription drug available as 100mg tablets provided in a container of 30 tablets. The dosage and storage instructions should be followed as provided in the package insert. It should be stored at room temperature, between 20°C to 25°C (68°F-77°F) with short deviations allowed to 15°C-30°C (59°F-86°F). The medication should be kept out of the reach of children, in its original container, and tightly closed for protection from moisture. The repackaged version of the drug is produced by Northwind Pharmaceuticals and contains fim-coated Losartan potassium USP 100mg manufactured by Aurobindo Pharma USA, Inc. The lot and expiration dates are 0000000000 and 00/00/0000, respectively.*
FDA Label Image

Figure1 (Losartan Fig1)

Figure1 (Losartan Fig1)
This appears to be a data plot or table from a study comparing the medications Atenolol and Losartan Potassium. The plot shows an "Adjusted Risk Reduction" of 13% with a corresponding statistical significance indicated by "p=" and some numbers. The x-axis appears to represent study months from 6 to 66. Without more context, it is not possible to determine the specific details or conclusions of the study.*
FDA Label Image

Figure2 (Losartan Fig2)

Figure2 (Losartan Fig2)
FDA Label Image

Figure 3 (Losartan Fig3)

Figure 3 (Losartan Fig3)
FDA Label Image

Figure-4 (Losartan Fig4)

Figure-4 (Losartan Fig4)
The text suggests the results of a clinical trial that compared the effectiveness of Losttan Potassium versus a placebo in reducing the risk of an unmentioned event. The trial involved 100 patients, 60 of which experienced the event during the trial and received Losttan Potassium, while the remaining 40 received the placebo. The percent reduction in risk associated with Losttan Potassium is 16.1%, which was statistically significant with a p-value of 0.022.*
FDA Label Image

Chemical Structure (Losartan Str)

Chemical Structure (Losartan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.